Humanized, nonmitogenic OKT3 antibody, huOKT3 gamma(Ala-Ala): initial clinical experience.
Woodle
E S
ES
Department of Surgery, Ben May Institute for Cancer Research, University of Chicago, Illinois, USA.
Bluestone
J A
JA
Zivin
R A
RA
Jolliffe
L K
LK
Auger
J
J
Xu
D
D
Thistlethwaite
J R
JR
D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000628:therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D016853:Muromonab-CD3 / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016035:Pancreas Transplantation / Q000276:immunology*; D013997:Time Factors
D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; C112844:monoclonal antibody huOKT3(Ala-Ala)